65,437 trials
Achondroplasia
Primary: Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind Treatment — 4.09; 4.52; 5.16; 5.42 cm/year — p== 0.6004
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 25; 0; 16.7; 0 Percentage of participants
Duchenne Muscular Dystrophy
Primary: Number of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) In Participants With Duchenne Muscular Dystrophy — 3; 5 Participants
Osteoarthritis, Shoulder
Primary: Numerical Rating Scale (NRS) Pain — -3.72 score on a scale — p=<0.0001
Acute Respiratory Distress Syndrome
Primary: Time to Clinical Improvement or Hospital Discharge up to Day 28 — NA; 19.0; NA; 22.0 days
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — NA; NA nanomole*hour/liter…
Melanoma · Metastatic Malignant Neoplasm in the Spine · Renal Cell Carcinoma
Primary: Distance Between the Gross Disease and Spinal Cord (Cord-disease Distance, CDD) of at Least 3mm After Treatment. — 1; 14 Participants
ASCVD · Elevated Cholesterol · Heterozygous Familial Hypercholesterolemia
Primary: Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk — 78.18; 79.07; 76.81; 78.43 Percentage of participants
Type 2 Diabetes Treated With Insulin
Primary: CGM Time Below 54 mg/dL — 0.00; 0.00; 0.00; 0.00 percentage of time
Migraine Headache
Primary: Improvement in Headache Pain Score — -3.3 score on a scale
Atrial Fibrillation · Pericardial Effusion · Pleural Effusion
Primary: Number of Participants With Postoperative Atrial Fibrillation — 39; 33 Participants
Parkinson Disease
Primary: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline…
Hemophilia A
Primary: Model-Based Annualized Bleeding Rate for Treated Bleeds — 27.0; 1.0; 1.0; 1.2 Treated bleeds per year — p=<0.0001
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
Cheek Augmentation
Primary: Assess Treatment With Restylane Volyme and Restylane Lyft Lidocaine Using GAIS — 20; 17; 9; 9 Participants